The nuclear factor of activated T cells (NFAT) regulates cytokine gene expression in T cells through cis-acting elements located in the promoters of cytokine genes. Here, we report the cDNA cloning, chromosomal localization, and initial characterization of a transcription factor related to NFATp and NFATc. The novel molecule, designated NFATx, exhibits in its middle a region very similar to the Rel homology domain in NFATc and NFATp. The amino-terminal region of NFATx also shows significant similarities to corresponding sequences in NFATc and NFATp and contains three copies of a conspicuous 17-residue motif of unknown function. We provide evidence showing that NFATx can reconstitute binding to the NFAT-binding site from the interleukin 2 promoter when combined with AP1 (c-Fos/c-Jun) polypeptides and that NFATx is capable of activating transcription of the interleukin 2 promoter in COS-7 cells when stimulated with phorbol ester and calcium ionophore. NFATx mRNA is preferentially and remarkably found in the thymus and at lower levels in peripheral blood leukocytes. The expression pattern of NFATx, together with its functional activity, strongly suggests that NFATx plays a role in the regulation of gene expression in T cells and immature thymocytes.
We demonstrated that the rox gene of Nocardia farcinica encodes a rifampicin monooxygenase capable of converting rifampicin to a new compound 2¢-N-hydroxy-4-oxo-rifampicin with a markedly lowered antibiotic activity. The deletion mutation (Drox) of the rox gene gave no significant influence to the rifampicin resistance of N. farcinica. However, transformation with a plasmid containing an overexpressing the rox gene markedly raised the rifampicin resistance in the strain with the deletion mutation of the rpoB2 gene as the principal rifampicin resistance determinant. On the other hand, rifampicin was decolorized by the wild-type strain, whereas it remained intact when incubated with the Drox strain. Based on these results, it will be conclusive that the rox gene is capable of initiating rifampicin degradation with a new metabolite formation at the first step and having a role as the secondary rifampicin resistance factor in N. farcinica.
Objective:
Human papillomavirus (HPV) vaccination was introduced in Japan in
April 2013, as a national immunization program for girls aged 12–16 years, after an
initial introduction in 2010 as a public-aid program for girls aged 13–16 years. The
Yuri-Honjo district had the highest vaccine coverage among women aged 17–51 years in 2017,
due to the original public-aid program. The aim of this study was to evaluate the
differences in the vaccine types of HPV16/18 infections between 2008–2012 (pre-vaccine
era) and 2013–2017 (vaccine era).
Materials and Methods:
We evaluated whether HPV vaccination was associated
with a decrease in the prevalence of HPV16/18 and high-risk HPV and the incidence of
HPV-associated cervical lesions. A total of 1,342 women aged 18–49 years, covering both
the pre-vaccine and vaccine eras, who visited Yuri Kumiai General Hospital and underwent
HPV genotype tests from June 2008 to December 2017 were compared.
Results:
Among women aged 18–24 years with higher vaccine coverage (68.2%),
the prevalence of HPV16/18 and high-risk HPV decreased from 36.7% and 69.4%, respectively,
in the pre-vaccine era to 5.8% and 50.0%, respectively, in the vaccine era (p=0.00013 and
p=0.047, respectively). Among those with cervical intraepithelial neoplasia grade 2− and
grade 2+, HPV16/18 prevalence decreased from 30.0% to 2.7% (p=0.0018) and from 81.8% to
36.4% (p=0.030), respectively. In this age group, the rate of HPV16/18 positivity
decreased significantly. Among age groups with lower vaccine coverage, HPV prevalence did
not significantly differ between the two eras.
Conclusion:
The prevalence of HPV16/18 and high-risk HPV significantly
decreased in women aged 18–24 years, most of whom were vaccinated. HPV vaccination
effectively reduced the prevalence of HPV16/18 infections in the Yuri-Honjo district.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.